Skip to main content
Download PDF

Prospective comparative multi-centre study on imported Plasmodium ovale wallikeri and Plasmodium ovale curtisi infections

Malaria Journal volume 17, Article number: 399 (2018) Cite this article

Abstract

Background

Few previous retrospective studies suggest that Plasmodium ovale wallikeri seems to have a longer latency period and produces deeper thrombocytopaenia than Plasmodium ovale curtisi. Prospective studies were warranted to better assess interspecies differences.

Methods

Patients with imported P. ovale spp. infection diagnosed by thick or thin film, rapid diagnostic test (RDT) or polymerase chain reaction (PCR) were recruited between March 2014 and May 2017. All were confirmed by DNA isolation and classified as P. o. curtisi or P. o. wallikeri using partial sequencing of the ssrRNA gene. Epidemiological, analytical and clinical differences were analysed by statistical methods.

Results

A total of 79 samples (35 P. o. curtisi and 44 P. o. wallikeri) were correctly genotyped. Males predominate in wallikeri group (72.7%), whereas were 48.6% in curtisi group. Conversely, 74.3% of curtisi group were from patients of African ethnicity, whilst 52.3% of Caucasians were infected by P. o. wallikeri. After performing a multivariate analysis, more thrombocytopaenic patients (p = 0.022), a lower number of platelets (p = 0.015), a higher INR value (p = 0.041), and shorter latency in Caucasians (p = 0.034) were significantly seen in P. o. wallikeri. RDT sensitivity was 26.1% in P. o. curtisi and 42.4% in P. o. wallikeri. Nearly 20% of both species were diagnosed only by PCR. Total bilirubin over 3 mg/dL was found in three wallikeri cases. Two patients with curtisi infection had haemoglobin under 7 g/dL, one of them also with icterus. A wallikeri patient suffered from haemophagocytosis. Chemoprophylaxis failed in 14.8% and 35% of curtisi and wallikeri patients, respectively. All treated patients with various anti-malarials which included artesunate recovered. Diabetes mellitus was described in 5 patients (6.32%), 4 patients of wallikeri group and 1 curtisi.

Conclusions

Imported P. o. wallikeri infection may be more frequent in males and Caucasians. Malaria caused by P. o. wallikeri produces more thrombocytopaenia, a higher INR and shorter latency in Caucasians and suggests a more pathogenic species. Severe cases can be seen in both species. Chemoprophylaxis seems less effective in P. ovale spp. infection than in P. falciparum, but any anti-malarial drug is effective as initial treatment. Diabetes mellitus could be a risk factor for P. ovale spp. infection.

Background

Malaria remains a global health problem with more than 212 million new cases in 2016 and 429,000 annual deaths worldwide, mostly driven by Plasmodium falciparum and Plasmodium vivax, to which most of the research resources are devoted [1].

Conversely, Plasmodium ovale spp. infection can be considered a neglected disease and little is known on its real incidence, geographic distribution, global disease burden or interactions with other Plasmodium species. The main problems for its study have been that it is frequently misdiagnosed because of usual submicroscopic or low parasitaemia levels, low performance of malaria rapid diagnostic tests (RDT) [2] and a majority of mixed infections with other Plasmodium spp. [3].

Nowadays, polymerase chain reaction (PCR) techniques have expanded the knowledge on P. ovale spp. epidemiology reporting infections in most of sub-Saharan Africa, Southeast Asia, and the Indian subcontinent [4,5,6], but not in the Americas, with prevalences as high as 15% in zones of Nigeria or Papua New Guinea [3]. In addition, severe complications, such as acute respiratory distress syndrome (ADRS) [7], spleen rupture, severe anaemia, or death may occur in patients with P. ovale spp. malaria [8]. Lastly, the incidence of imported P. ovale spp. infection seems to be increasing among travellers returning from West Africa [9,10,11], in whom chemoprophylaxis failed to work more frequently [12] compared to P. falciparum or P. vivax [13].

Since the study by Sutherland et al. was published in 2010, P. ovale is considered to comprise two genetically different subspecies, named P. ovale curtisi and P. ovale wallikeri that could have diverged 1–2 million years ago in their evolution [4]. They both are morphologically identical and cannot be differentiated by microscopy. Increasing information from different studies in endemic countries support that both subspecies co-circulate in Africa and Asia and are unable to recombine genetically [14,15,16,17].

Once established the genetic differences, the next question was to find out if there were any other differences in epidemiology, microbiology or clinical features between both subspecies. Plasmodium o. curtisi and P. o. wallikeri do not seem to differ in parasitaemia levels [5, 9, 13] and the absence of Schüffner’s stippling may be a feature specific to P. o. wallikeri but only in 30% of blood samples [9]. Clinical differences between both species have not been clearly established, but P. o. wallikeri may have a shorter period of latency [13].

Recently, a multicentre, retrospective study in Spain was reported, comparing 21 imported P. o. curtisi and 14 P. o. wallikeri infections confirmed by PCR and gene sequencing [5]. The only significant finding was more severe thrombocytopaenia among patients with P. o. wallikeri infection than among those with P. o. curtisi (p = 0.031). However, non-significant trends showing shorter latency, lower albumin level, higher temperature and markers of more severe haemolysis were found in P. o. wallikeri group. Because of the retrospective design and small number of patients, larger, prospective studies were warranted to confirm these findings. Therefore, the results of a multicentre, prospective, comparative study of imported P. o. wallikeri and P. o. curtisi infections conducted in several European countries during the period 2014–2017 are presented below.

Methods

Study design

A prospective, observational, un-randomized, open-label, multicentre study was performed at European hospitals of TropNet Europe, European Network for Tropical Medicine and Travel Health. Participants were recruited between March 2014 and May 2017. The study was approved by the University Hospital Príncipe de Asturias Ethical Board and at each site as needed. Written informed consent was obtained from the participant or a legal representative before enrolment in the study. The trial was conducted in accord with the Declaration of Helsinki and Good Clinical Practice.

Microbiologic diagnosis

The initial diagnosis of imported P. ovale spp. infection was made up by thick and/or thin film and/or second generation RDT and/or PCR available in each hospital. Blood smears were stained by a standard technique with Giemsa solution for 30 min and were reviewed by an expert microbiologist. Parasite count was measured by determining the proportion of parasitized erythrocytes or the number of trophozoites per microlitre. Mixed infections with other Plasmodium species were excluded.

Laboratory samples

For cases tested positive, three drops (≈ 50 μL) of full blood left after routine laboratory tests, were dotted on filter paper (Whatman™) and sent by regular mail to the Reference Malaria & Emerging Diseases Laboratory of the National Centre of Microbiology in Madrid. If DNA of P. ovale spp. had already been isolated, this was sent into a 1.5 mL screw cap tube with complete closure to the same Reference Laboratory.

Isolation of parasite DNA and molecular diagnosis confirmation

DNA isolation was performed using the QIAamp DNA blood mini kit (QIAGEN®) from whole blood following the manufacturer’s protocol. Molecular diagnosis confirmation of P. ovale spp. was carried out by semi-nested multiplex malaria PCR [18] which allows to distinguish the four more prevalent human malaria species.

Plasmodium ovale subspecies characterization and confirmation

Characterization of P. o. curtisi and P. o. wallikeri was performed by partial sequencing of the ssrRNA gene and ssrRNA amplification was performed by a nested PCR assay specific for Plasmodium genus. The first reaction included UNR (5′-GACGGTATCTGATCGTCTTC-3′) and PLF (5′-AGTGTGTATCCAATCGAGTTTC-3′) primers [18]. The second PCR reaction incorporates the products of the first reaction along with NewPLFsh (5′-CTATCAGCTTTTGATGTTAG-3′) and NewRevsh (5′-CCTTAACTTTCGTTCTTG-3′) primers. Infection with different malaria species yields products of different sizes between 710 and 740 bp.

The PCR mixture in both reactions consisted of 75 mM TrisHCl (pH 9.0), 2 mM MgCl2, 50 mM KCl, 20 mM (NH4)2SO4, 200 μM of dNTP, 0.075 µM of each primers, 1.25 units of Taq DNA polymerase (Biotools B&M Labs., S.A., Madrid, Spain), and 5 μL of DNA, extracted by QIAgen kit, was used as template in a reaction volume of 50 μL. For the second reaction mixture, 2 µL of the PCR product of the first reaction was used as template. For both reactions, a GeneAmp® PCR System 2700 thermal cycler (Applied Biosystems Laboratory) was used, beginning with 7 min at 94 °C, followed by (first-round) 40 cycles of 20 s at 94 °C, 20 s at 62 °C, and 30 s at 72 °C, or (second-round) 35 cycles of 20 s at 94 °C, 20 s at 53 °C, and 20 s at 72 °C. The final cycle was followed by an extension time of 10 min at 72 °C.

The amplified products were purified using Illustra DNA and Gel Band Purification Kit (General Electric Healthcare) and sequenced with the Big Dye Terminator v3.1 Cycle Sequencing in an ABI PRISM® 3700 DNA Analyzer. All amplified products were sequenced in both directions twice.

In order to confirm P. ovale subtyping, a nested PCR amplification plus sequencing targeting cytochrome b was performed in three samples of each group.

Data collection

An anonymized database was designed to input all the medical information and laboratory registries in a prospective way. Data collected included gender, age, ethnicity, underlying diseases, type of patient, dates and purpose of travel, countries visited, malaria chemoprophylaxis, date of admission and diagnosis, presenting clinical signs or symptoms and complications of severe malaria according to criteria of the World Health Organization (WHO) [19] where no threshold of parasitaemia for P. ovale spp. was established. The closest possible date of inoculation was defined as the day of departure from a malaria endemic area. The time between date of arrival and onset of illness or diagnoses was calculated once asymptomatic patients were excluded. Patients were classified as an early immigrant if they had stayed in a country without malaria for less than a year prior to diagnosis. An immigrant was a VFR (visiting friends and relatives) if travelled to a country endemic of malaria after a year of stay in a non-malarial area, and VFR traveller if visited his/her first-degree relative’s country of birth having been born in a non-malaria endemic country. Recent Plasmodium infection was defined as probable or definite malaria infection in the previous 12 months before P. ovale spp. diagnosis.

Laboratory results included microbiological data with parasitaemia count, full blood count with white blood cells, haemoglobin and platelets, values of glucose, creatinine, albumin, transaminases, lactate dehydrogenase (LDH), total bilirubin (tBR) in plasma, the coagulation parameters activated partial thromboplastin time (APTT) and international normalized ratio (INR), glucose-6-phosphate dehydrogenase (G6PDH) activity in red blood cells, as well as serological studies of infection with human immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis C (HCV). Thrombocytopaenia was defined as a platelet count under 150,000/µL. Treatments, clinical and microbiological evolution and duration of hospital stay of those admitted were recorded. Treatments were performed following the guidelines of each country and health centre without a common recommendation.

Statistical analysis

Differences of proportions were evaluated by the Chi-squared-test if less than 20% of cells had five or less expected values. If more than 20% of cells had five or less expected values we used the Fisher’s exact test for categorical variables. Differences of means between groups were calculated by the Student’s t-test for independent samples if the normal distribution could be assumed. In the Student’s t test for independent samples, the Levene’s test for homogeneity of variances was used. If normal distribution was not valid, the non-parametric Mann–Whitney U-test was performed. To test for normality, either the Shapiro–Wilks for small samples or the Kolmogorov–Smirnov with Lilliefors’ correction for large samples were used. Values are reported as number of patients and percentage or, for non-parametric distributions, as median and interquartile range (IQR). A multivariate linear regression analysis was performed for continuous variables and multivariate logistic regression for categorical variables to confirm if real differences were found when non-homogenous population between both groups were identified. A two-sided p value of 0.05 or less was considered to indicate statistical significance. Statistical analysis was performed using the SPSS version 21 (SPSS Inc, Chicago, IL, USA).

Results

During the period of the study, a total of 96 blood samples from 29 hospitals were sent to the reference laboratory. Of them, 13 were excluded because of mixed infections (11 with P. falciparum, 1 with P. vivax and 1 with Plasmodium malariae), 2 samples did not get amplified and data from another 2 were not obtained. At the end, 79 correctly genotyped and with complete patient information were included for statistic analysis. Of them, 35 were identified as P. o. curtisi and 44 as P. o. wallikeri.

Table 1 presents demographic and epidemiological data from both groups. A significant difference in the distribution of gender, ethnicity and type of patients was shown. Males clearly predominate in wallikeri group whereas gender distribution was more evenly matched in the curtisi group. Conversely, on ethnicity, African patients were 74.3% of curtisi group. This ethnic distribution is reflected in the type of patient with a majority of VFR and recent immigrants in the P. o. curtisi infection versus a larger number of displaced for working or cooperation in the other species. The remaining epidemiological data did not differ including country of infection, duration of travel, chemoprophylaxis, latency time, time until diagnoses, recent Plasmodium infection or underlying diseases. There is a wide range of 21 countries as the place of infection, most of them in West Africa.

Table 1 Demographic and epidemiological characteristics
Full size table

Microbiological and laboratory information is reported in Table 2. Several analytical parameters showed statistically significant differences such as total leukocyte and platelet count, number of thrombocytopaenic patients, haemoglobin, creatinine, LDH or INR values. Even after the multivariate study was performed, eliminating the confounding factor of ethnicity, the number of platelets, thrombocytopaenic patients and INR remained significant (Table 3). Latency time was also included in the multivariate analysis because of the significant difference found in a previous report [13]. A statistically shorter latency period also appeared, but only in Caucasians patients with P. o. wallikeri compared to those in the curtisi group. On the other hand, no difference in parasitological data including submicroscopic infection, parasitaemia or sensitivity of the common antigen of RDT was seen.

Table 2 Microbiological and analytical characteristics
Full size table
Table 3 Multivariate linear regression and multivariate logistic regression analysis related to ethnicity of parameters with significant differences in univariate analysis and latency time
Full size table

In respect of the clinical manifestations and time of hospitalization no differences were found in (Table 4). Treatments were widely different according to the protocols of each centre. Primaquine was supplied to most patients in both groups and only three patients showed G6PDH deficiency that contraindicated this treatment. Five patients showed analytical criteria for severe malaria and another one a rare and severe complication (haemophagocytosis). Outcome in nearly all cases was good, although two patients did not receive any anti-malarial treatment due to loss of follow-up.

Table 4 Clinical and therapeutic characteristics
Full size table

Discussion

This is the largest prospective study to date on the two species of infection by imported P. ovale trying to overcome recruitment difficulties and limitations of previous retrospective studies.

On the results obtained, significant differences were found in the epidemiological characteristics of sex, ethnicity and type of patients between both groups. Ethnic differences may be the main confounding factor since there is a greater probability that African patients retain some semi-immunity against P. ovale spp. infection (excluding VFR travellers), which would generally result in less clinical and analytical involvement [20]. On the other hand, the difference in sex distribution and type of patients seems to be clearly related to the ethnic origin since in a subgroup analysis, 16 out of 18 (89%) of the patients with P. o. wallikeri who travelled by international cooperation were male and Caucasians, which would bias the characteristics of this group.

This distribution could be a result of chance alone or due to the fact that actually Caucasians patients are more susceptible to infection by wallikeri parasites. However, a previous retrospective study did not show these differences in sex, ethnicity or type of patient [5] and the few studies of imported ovale malaria reporting a significant number of patients showed either equality of sexes (but did not report on ethnicity) [13] or they were nearly all Chinese men who worked in African countries [10].

When performing the multivariate study adjusted by ethnicity to reduce this confounding factor, the number of patients with thrombocytopaenia and two of the analytical alterations remained significant. Thrombocytopaenia was more pronounced in P. o. wallikeri and INR values were higher in the wallikeri group. The comparation of the rest of analysis variables were not finally significant, over all those that indicate a greater degree of haemolysis, such as LDH, tBR or haemoglobin level.

In the case of thrombocytopaenia, these results confirm the main finding of a previous retrospective study where the only difference was more severe thrombocytopaenia in P. o. wallikeri infection [5]. Thrombocytopaenia is a common finding in patients with malaria of all Plasmodium species ranging from 24 to 94% of indicence, although spontaneous haemorrhages are infrequent and limited to very severe cases [21]. Also it is of note that thrombocytopaenia seems to be a very common finding in P. ovale spp. infection. Of the 79 patients analysed, 53 (67%) had under 150,000 platelets/µL, which corresponds to our previous series findings of 66.6% in 16 imported ovale infection patients [22] and a retrospective study where 26 out of 35 patients (75.3%) suffered from thrombocytopaenia [5]. Only one patient in each group showed under 50,000 platelets/µL again without any haemorrhagic feature.

The pathogenesis of thrombocytopaenia in malaria is not fully understood but is accepted that encompasses several different mechanisms that lead to increased platelet destruction or consumption, such as increased attachment to endothelium and adherence to Von Willebrand factor, clumping and agglutination of infected and uninfected erythrocytes, consumption into the coagulation process and haemolysis, increased diffuse platelet sequestration, decreased nitric oxide bioavailability, and immune complexes-mediated destruction [23].

Although thrombocytopaenia is not among the severity criteria of the WHO, evidence is accumulating that it can predict an adverse outcome, which seems to be driven by a greater severity of illness in P. falciparum or P. vivax [21, 24] and severe thrombocytopaenia can identify an increased risk of death from falciparum or vivax malaria [25]. Therefore, in the case of P. o. wallikeri it could indicate a greater intrinsic pathogenicity of this species compared to P. o. curtisi, although without evidence of any major significantly worse clinical criteria of severity.

Regarding the other significant finding of this study, the higher INR elevation in P. o. wallikeri compared to P. o. curtisi, this increase was always mild and in no case exceeded the value of 1.54 nor was related to any bleeding. On the other hand, the APTT values were similar in both groups. No other coagulation factors, fibrinogen levels, fibrin degradation products or d-dimer were measured that could argue in favour of a significant coagulation disorder.

It is well known that P. falciparum malaria is associated with significant coagulation activation. The increase in INR or its equivalent, prolongation of prothrombin time, is produced by the activation of the extrinsic pathway of the coagulation cascade and can lead to disseminated intravascular coagulation in the most severe cases of malaria. Plasmodium falciparum seems to trigger coagulation activation through multiple different pathways although the mechanisms involved are not well understood [26]. Much less information on coagulation is available in P. ovale spp. infection. In the case of INR, the finding of this study might support the hypothesis of a more pathogenic wallikeri parasite, but does not seem to pose a significant clinical difference or severity.

In the initial analysis, no differences were found in the latency period, but when the multivariate analysis was performed a significant shorter time appeared in P. o. wallikeri compared to P. o. curtisi infection, but only in Caucasians patients. This difference is more significant since only one of the seven Caucasians patients who suffered infection by P. o. curtisi had taken adequate prophylaxis versus 11 out of 22 (50%) of the wallikeri group, which should have lengthened their latency. The retrospective study by Nolder et al. in the UK also found significant shorter latency period in wallikeri cases but did not report the ethnicity or patient characteristics [13]. On the contrary, another study in Chinese people (ethnically homogeneous but with unknown previous exposure to malaria or chemoprophylaxis use) encompassing 109 P. o. curtisi and P. o. wallikeri [10] imported from Africa, did not find any difference in latency. In a previous retrospective study, only a trend to shorter wallikeri latency was found (p = 0.07) [5].

These results of different latency times in only Caucasians patients suggest a strong influence of the previous partial immunity to malaria in the time of symptoms of P. ovale spp. infection. Finally, note that in both species latencies greater than 1 year have been found as described previously [11].

A complete chemoprophylaxis was reported in 22.8% of ovale spp. infections and up to 35% in P. o. wallikeri, a high percentage if compared with data from large series of imported malaria as in USA 2014, where only 7.8% of travellers correctly took prophylaxis [11]. If analysed by Plasmodium species, these results are similar to the study by Nolder et al. which stated that the proportion of ovale malaria which occurred in patients reporting chemoprophylaxis use (33%) was significantly higher than for P. falciparum (6.4%) and P. vivax (23.7%) [13]. Also, in a USA and Israel study, up to 73% of imported P. ovale spp. used an effective prophylaxis [27]. Moreover, in a recent Spanish study considering only the subgroup of travellers with P. ovale/P. vivax malaria, these patients had also taken chemoprophylaxis significantly more frequently than those with non-P. ovale/P. vivax malaria (35.5% vs. 2.7%) [28]. These results reinforce the idea that current prophylaxis does not adequately act on P. ovale spp. infection, since it is ineffective against its hypnozoites and, therefore, does not prevent a delayed primary attack or true relapses from occurring when there is no prophylactic medication in blood.

Although the information cannot be completely reliable, over 40% of patients reported an episode of malaria in the previous 12 months. This could have been a primary infection by P. ovale, another ovale relapse, a mixed infection with other Plasmodium or simply a non-ovale malaria unrelated to the current episode. Since it is not feasible to obtain a previous diagnostic sample, it is impossible to know if the current episode represented a primary infection or a relapse by P. ovale. Primary infection could only be diagnosed in the cases of first malarial episode and very short latency period.

Regarding the underlaying conditions, it is worth focusing on diabetes mellitus and drepanocytosis. The prevalence of diabetes mellitus is increasing worldwide, especially in low income countries, as are found in sub-Saharan Africa [29]. The number of diabetics in this study is as high as 6.32% (5/79) in a population with a low average age, especially in wallikeri group. In a retrospective curtisi–wallikeri study up to 8.5% of patients suffered from diabetes [5] and in a previous study of imported P. ovale infection 3 out of 16 patients (18.7% with mean age 30.6 years) were also diabetics [22]. A recent Swedish study, reported diabetes in 3.5% of 937 patients with imported P. falciparum and 2.5% in 398 imported malaria in a Spanish Tropical Medicine Centre [30]. In a series of 229 P. falciparum infections from 2006 to 2015 in Hospital Universitario Príncipe de Asturias (HUPA), 2.6% were diabetics (unpublished data). As diabetes is a known risk factor for malaria due to P. falciparum in endemic areas [31], the higher prevalence of this chronic disease in P. ovale studies might indicate that would also be a risk factor, and deserves further investigation to confirm this finding.

In endemic areas, carrying the sickle cell trait represents a risk factor for infection by P. ovale spp. [20] and a partial protective factor against severe P. falciparum infection. In this study, 2 out of 47 African patients (4.2%) had drepanocytosis. Moreover, in the previous comparative retrospective study, 8.3% (2 out of 24) showed drepanocytosis and up to 23% (3/13) in the series of 16 imported P. ovale spp. [22]. Gathering African patients from the three studies (7/84) and comparing to 1.35% of patients in 221 African people with imported P. falciparum in HUPA during the period 2006–2015 (unpublished data) significant difference can be found (p < 0.005) that would support the results of the study conducted in endemic area.

As in previous studies, no differences were detected in parasitaemias between both groups [6, 9, 32]. Most of them had low parasite counts clearly below 1%, making it even more difficult to find statistically real differences. Surprisingly, two patients reached 2% parasitaemia, a Caucasian traveller without any immunity to malaria and a child with drepanocytosis and intense anaemia that enhanced the proportion of infected red blood cells. Such high parasitaemia has been rarely described, sometimes linked to serious complications such as spleen rupture [33]. Finally, the absence of Schüffner’s stippling in blood smear, which has been described as a possible feature specific to P. o. wallikeri, was not studied.

There was also no difference in the sensitivity of RDTs, which was low as described in the literature [2] without exceeding 45% in either group. Almost 20% of the cases in both groups were diagnosed only by PCR, as RDT and/or thick blood smears were negative. In endemic areas this percentage is much higher, especially in asymptomatic patients [3]. Therefore, if the clinical and epidemiological suspicion is high, it would be convenient to repeat the diagnostic tests and request molecular PCR techniques not to miss P. ovale spp. diagnosis.

This study confirms that this infection can cause malaria with severity criteria or complications, in this case 7.6% of all patients with no differences between both species. In series of imported malaria by P. falciparum the rate of severe cases was around 2–17% [11, 34], but with a much higher incidence of life-threatening complications, such as ADRS, severe anaemia or cerebral malaria than described in P. ovale spp. infection [8]. A rare case of haemophagocytosis was included that had been described only in P. falciparum and P. vivax infection [35], but not in P. ovale spp. Analysing the six patients with severe malaria or complications, two had drepanocytosis (which also produces anaemia) and one was diabetic, which might indicate the possible importance of these risk factors in the severity of P. ovale spp. infection.

In cases of malaria with tBR > 3 mg/dL, the WHO severity criteria add parasitaemia levels above 100,000/µL in P. falciparum and > 20,000/µL in P. vivax and Plasmodium knowlesi, but is not known in the case of P. ovale spp. In this study, all four cases with tBR > 3 mg/dL had parasitaemias over 4000/µL. In addition, four patients received parenteral artesunate, two of them with tBR > 3 mg/dL and one with unusually high parasitaemias of 2%. It is described that host response may reach full strength at lower parasitaemia in P. vivax and P. ovale spp. infection than in P. falciparum [36] so, perhaps it would be also convenient to establish a threshold of parasitaemia with jaundice and hyperparasitaemia in P. ovale spp. in the face of treatment decisions and outcome.

The treatments were very varied, including artemisinins alone or in combination, atovaquone/proguanil, chloroquine or quinine-doxycycline, all with good initial clinical evolution, which is compatible with the sensitivity of P. ovale spp. described for multiple antimalarials [8]. Over 70% of them received primaquine with good tolerance, although there was no long-term follow-up recorded to assess episodes of relapse or late recrudescence.

The prospective study design has minimized some of the limitations of the previous retrospective study but some of them still remain. First, although it is one of the largest studies carried out worldwide, the number of patients may still lack sufficient statistical power to show other differences between infections with both P. ovale species. Second, only strains of P. ovale from Africa, and patients from Africa and Europe were analysed; a study of infections and patients from Asia, Oceania or other places might show different results. Third, the behaviour of these species in endemic countries may be different but it would be difficult to gather a significant number of patients with P. ovale spp. monoinfection due to the high prevalence of mixed Plasmodium infections and malaria reinfections. Fourth, the date of infection is a minimal approximate and it is virtually impossible to distinguish a primary infection from a relapse. Last, a mix of ethnicities, non-immune and semi-immune patients led to heterogeneous study groups, although the multivariate statistical study has reduced this bias.

Conclusions

In this study, imported P. o. wallikeri infection was more frequent in males and Caucasian patients than in P. o. curtisi group. Malaria caused by P. o. wallikeri produced more thrombocytopenic patients, more marked thrombocytopaenia and a higher INR than P. ovale curtisi, although without other clinical or severity differences. Plasmodium o. wallikeri malaria had shorter latency, but only in Caucasian patients. These findings suggest that wallikeri species might be somewhat more pathogenic than P. ovale curtisi. Some cases with severity criteria were seen in both species and required treatment with intravenous artesunate. The clinical evolution with any anti-malarial drug was usually good, however, chemoprophylaxis seemed less effective in P. ovale spp. infection than in the case of P. falciparum. Diabetes mellitus might also be a risk factor for P. ovale spp. infection such as drepanocytosis. Current RDT was shown to have low diagnostic sensitivity in both species and PCR was essential for diagnosis in a significant percentage of cases.

Abbreviations

ADRS:

acute respiratory distress syndrome

APTT:

activated partial thromboplastin time

DNA:

deoxyribonucleic acid

G6PDH:

glucose-6-phosphate dehydrogenase

HBV:

hepatitis B virus

HCV:

hepatitis C virus

HIV:

with human immunodeficiency virus

INR:

international normalized ratio

IQR:

interquartile range

LDH:

lactate dehydrogenase

PCR:

polymerase chain reaction

RDT:

rapid diagnostic test

ssrRNA:

small-subunit ribosomal ribonucleic acid

tBR:

total bilirubin

VFR:

visiting friends and relatives

WHO:

World Health Organization

References

  1. 1.

    WHO. World malaria report 2016. Geneva: World Health Organization; 2015. http://apps.who.int/iris/bitstream/10665/252038/1/9789241511711-eng.pdf?ua=1. Accessed 26 Nov 2017.

  2. 2.

    Maltha J, Gillet P, Jacobs J. Malaria rapid diagnostic tests in travel medicine. Clin Microbiol Infect. 2013;19:408–15.

    CAS  Article  Google Scholar 

  3. 3.

    Mueller I, Zimmerman PA, Reeder JC. Plasmodium malariae and Plasmodium ovale—the “bashful” malaria parasites. Trends Parasitol. 2007;23:278–83.

    CAS  Article  Google Scholar 

  4. 4.

    Sutherland CJ, Tanomsing N, Nolder D, Oguike M, Jennison C, Pukrittayakamee S, et al. Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally. J Infect Dis. 2010;201:1544–50.

    CAS  Article  Google Scholar 

  5. 5.

    Rojo-Marcos G, Rubio-Muñoz JM, Ramírez-Olivencia G, García-Bujalance S, Elcuaz-Romano R, Díaz-Menéndez M, et al. Comparison of imported Plasmodium ovale curtisi and P. ovale wallikeri infections among patients in Spain, 2005–2011. Emerg Infect Dis. 2014;20:409–16.

    CAS  Article  Google Scholar 

  6. 6.

    Bauffe F, Desplans J, Fraisier C, Parzy D. Real-time PCR assay for discrimination of Plasmodium ovale curtisi and Plasmodium ovale wallikeri in the Ivory Coast and in the Comoros Islands. Malar J. 2012;11:307.

    Article  Google Scholar 

  7. 7.

    Rojo-Marcos G, Cuadros-González J, Mesa-Latorre JM, Culebras-López AM, de Pablo-Sánchez R. Acute respiratory distress syndrome in a case of Plasmodium ovale malaria. Am J Trop Med Hyg. 2008;79:391–3.

    Article  Google Scholar 

  8. 8.

    Groger M, Fischer HS, Veletzky L, Lalremruata A, Ramharter M. A systematic review of the clinical presentation, treatment and relapse characteristics of human Plasmodium ovale malaria. Malar J. 2017;16:112.

    Article  Google Scholar 

  9. 9.

    Phuong MS, Lau R, Ralevski F, Boggild AK. Parasitological correlates of Plasmodium ovale curtisi and Plasmodium ovale wallikeri infection. Malar J. 2016;15:550.

    Article  Google Scholar 

  10. 10.

    Cao Y, Wang W, Liu Y, Cotter C, Zhou H, Zhu G, et al. The increasing importance of Plasmodium ovale and Plasmodium malariae in a malaria elimination setting: an observational study of imported cases in Jiangsu Province, China, 2011–2014. Malar J. 2016;15:459.

    Article  Google Scholar 

  11. 11.

    Mace KE, Arguin PM. Malaria surveillance—United States, 2014. MMWR Surveill Summ. 2017;66:1–24.

    Article  Google Scholar 

  12. 12.

    Gallien S, Taieb F, Schlemmer F, Lagrange-Xelot M, Atlan A, Sarfati C, et al. Failure of atovaquone/proguanil to prevent Plasmodium ovale malaria in traveler returning from Cameroon. Travel Med Infect Dis. 2008;6:128–9.

    Article  Google Scholar 

  13. 13.

    Nolder D, Oguike MC, Maxwell-Scott H, Niyazi HA, Smith V, Chiodini PL, et al. An observational study of malaria in British travellers: Plasmodium ovale wallikeri and Plasmodium ovale curtisi differ significantly in the duration of latency. BMJ Open. 2013;3(5):e002711.

    Article  Google Scholar 

  14. 14.

    Miller RH, Obuya CO, Wanja EW, Ogutu B, Waitumbi J, Luckhart S, et al. Characterization of Plasmodium ovale curtisi and P. ovale wallikeri in Western Kenya utilizing a novel species-specific real-time PCR assay. PLoS Negl Trop Dis. 2015;9:e0003469.

    Article  Google Scholar 

  15. 15.

    Fuehrer HP, Habler VE, Fally MA, Harl J, Starzengruber P, Swoboda P, et al. Plasmodium ovale in Bangladesh: genetic diversity and the first known evidence of the sympatric distribution of Plasmodium ovale curtisi and Plasmodium ovale wallikeri in southern Asia. Int J Parasitol. 2012;42:693–9.

    Article  Google Scholar 

  16. 16.

    Lalremruata A, Jeyaraj S, Engleitner T, Joanny F, Lang A, Bélard S, et al. Species and genotype diversity of Plasmodium in malaria patients from Gabon analysed by next generation sequencing. Malar J. 2017;16:398.

    Article  Google Scholar 

  17. 17.

    Oguike MC, Betson M, Burke M, Nolder D, Stothard JR, Kleinschmidt I, et al. Plasmodium ovale curtisi and Plasmodium ovale wallikeri circulate simultaneously in African communities. Int J Parasitol. 2011;41:677–83.

    Article  Google Scholar 

  18. 18.

    Rubio JM, Post RJ, van Leeuwen WM, Henry MC, Lindergard G, Hommel M. Alternative polymerase chain reaction method to identify Plasmodium species in human blood samples: the semi-nested multiplex malaria PCR (SnM-PCR). Trans R Soc Trop Med Hyg. 2002;96(Suppl 1):S199–204.

    Article  Google Scholar 

  19. 19.

    WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015. http://www.who.int/malaria/publications/atoz/9789241549127/en/. Accessed 20 Apr 2018.

  20. 20.

    Faye FB, Spiegel A, Tall A, Sokhna C, Fontenille D, Rogier C, et al. Diagnostic criteria and risk factors for Plasmodium ovale malaria. J Infect Dis. 2002;186:690–5.

    Article  Google Scholar 

  21. 21.

    Lacerda MV, Mourão MP, Coelho HC, Santos JB. Thrombocytopenia in malaria: who cares? Mem Inst Oswaldo Cruz. 2011;106(Suppl 1):52–63.

    Article  Google Scholar 

  22. 22.

    Rojo-Marcos G, Cuadros-González J, Gete-García L, Gómez-Herruz P, López-Rubio M, Esteban-Gutierrez G. Plasmodium ovale infection: description of 16 cases and a review. Enferm Infecc Microbiol Clin. 2011;29:204–8 (in Spanish).

    Article  Google Scholar 

  23. 23.

    Thachil J. Platelets and infections in the resource-limited countries with a focus on malaria and viral haemorrhagic fevers. Br J Haematol. 2017;177:960–70.

    Article  Google Scholar 

  24. 24.

    Willmann M, Ahmed A, Siner A, Wong IT, Woon LC, Singh B, et al. Laboratory markers of disease severity in Plasmodium knowlesi infection: a case control study. Malar J. 2012;11:363.

    Article  Google Scholar 

  25. 25.

    Lampah DA, Yeo TW, Malloy M, Kenangalem E, Douglas NM, Ronaldo D, et al. Severe malarial thrombocytopenia: a risk factor for mortality in Papua, Indonesia. J Infect Dis. 2015;211:623–34.

    Article  Google Scholar 

  26. 26.

    O’Sullivan JM, Preston RJ, O’Regan N, O’Donnell JS. Emerging roles for hemostatic dysfunction in malaria pathogenesis. Blood. 2016;127:2281–8.

    Article  Google Scholar 

  27. 27.

    Schwartz E, Parise M, Kozarsky P, Cetron M. Delayed onset of malaria—implications for chemoprophylaxis in travelers. N Engl J Med. 2003;349:1510–6.

    CAS  Article  Google Scholar 

  28. 28.

    Norman FF, López-Polín A, Salvador F, Treviño B, Calabuig E, Torrús D, et al. Imported malaria in Spain (2009–2016): results from the +REDIVI Collaborative Network. Malar J. 2017;16:407.

    Article  Google Scholar 

  29. 29.

    Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–49.

    CAS  Article  Google Scholar 

  30. 30.

    Ramírez-Olivencia G, Herrero MD, Subirats M, de Juanes JR, Peña JM, Puente S. Imported malaria in adults. Clinical, epidemiological and analytical features. Rev Clin Esp. 2012;212:1–9 (in Spanish).

    Article  Google Scholar 

  31. 31.

    Danquah I, Bedu-Addo G, Mockenhaupt FP. Type 2 diabetes mellitus and increased risk for malaria infection. Emerg Infect Dis. 2010;16:1601–4.

    Article  Google Scholar 

  32. 32.

    Starzengruber P, Fuehrer HP, Ley B, Thriemer K, Swoboda P, Habler VE, et al. High prevalence of asymptomatic malaria in south-eastern Bangladesh. Malar J. 2014;13:16.

    Article  Google Scholar 

  33. 33.

    Facer CA, Rouse D. Spontaneous splenic rupture due to Plasmodium ovale malaria. Lancet. 1991;338:896.

    CAS  Article  Google Scholar 

  34. 34.

    Seringe E, Thellier M, Fontanet A, Legros F, Bouchaud O, Ancelle T, et al. Severe imported Plasmodium falciparum malaria, France, 1996–2003. Emerg Infect Dis. 2011;17:807–13.

    Article  Google Scholar 

  35. 35.

    Ohnishi K, Mitsui K, Komiya N, Iwasaki N, Akashi A, Hamabe Y. Clinical case report: falciparum malaria with hemophagocytic syndrome. Am J Trop Med Hyg. 2007;76:1016–8.

    Article  Google Scholar 

  36. 36.

    Hemmer CJ, Holst FG, Kern P, Chiwakata CB, Dietrich M, Reisinger EC. Stronger host response per parasitized erythrocyte in Plasmodium vivax or ovale than in Plasmodium falciparum malaria. Trop Med Int Health. 2006;11:817–23.

    Article  Google Scholar 

Download references

Authors’ contributions

GRM, JMR, JCG and JMRG made substantial contributions to conception and design of this study. GMR, JMR, AA, FG and JCG made substantial contributions to analysis and interpretation of data. SJ, SGB, LRT, NRV, MGR, IMR, MCM, EME, MEG and JLT made substantial contributions to acquisition of data. GRM, JMR, JCG, JSC and RLV were involved in drafting the manuscript. All authors revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Acknowledgements

We thank all patients who kindly participated in this study. We also thank every doctor from 29 hospitals who contributed with their time to enroll patients and collect information: Mar Lago-Nuñez. Hospital Universitario La Paz-Carlos III, Madrid, Spain. Fancesco Castelli. Spedali Civili di Brescia, Italy. Jerónimo Jaquetti. Hospital Universitario de Fuenlabrada, Madrid, Spain. Carles Alonso. Hospital General l’Hospitalet - Consorci Sanitari Integral, Barcelona, Spain. Daniel Camprubí. Hospital Clinic, Barcelona, Spain. Miguel Górgolas-Hernández-Mora. Fundación Jiménez Díaz, Madrid, Spain. Guillermo Cuevas-Tascón. Hospital Infanta Leonor, Vallecas, Madrid, Spain. Ana Pérez-Ayala. Hospital Universitario 12 de Octubre, Madrid, Spain. María Teresa Guzmán-GarcíaMonge. Hospital Infanta Cristina, Parla, Spain. Mónica Ribell-Bachs. Hospital General de Granollers, Barcelona, Spain. Nuria Serre-Delcor, Hospital Vall D´Hebron-Drassanes, Barcelona, Spain. Yasmina Martín-Martín. Hospital General de Lanzarote, Las Palmas, Spain. Germán Ramírez-Olivencia. Hospital Gómez Ulla, Madrid, Spain. Rosario Cogollos-Agruña. Hospital Universitario de Móstoles, Madrid, Spain. Francisco Jesús Merino-Fernández. Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain. Antonia García-Castro. Hospital Río Carrión, Palencia, Spain. Purificación Cantudo-Muñoz. Hospital Universitario San Agustín. Linares, Jaén, Spain. Moncef Belhassen-García. Hospital Universitario de Salamanca, Spain. Pablo Martín-Rabadán. Hospital Universitario Gregorio Marañón, Madrid, Spain. Purificación Rubio-Cuevas. Hospital General Universitario de Valencia, Spain. Elena Trigo-Esteban. Hospital Universitario La Paz-Carlos III, Madrid, Spain. Juan Arévalo-Serrano. Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain.

The authors thank Dr. Francisco Javier Vilar (Consultant in Infectious Diseases, Pennine Acute Hospital NHS Trusts, Manchester, UK) for reviewing the manuscript.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The datasets used for analysis of the study are available from the corresponding author upon receipt of reasonable request.

Consent for publication

Not applicable.

Ethics approval and consent to participate

This study was approved by the University Hospital Príncipe de Asturias Ethical Board and at each site as needed. Written informed consent was obtained from the participant or a legal representative before enrolment in the study. Each patient was informed of the nature, aims and voluntarity of the study with the option to withdraw at any time. A code number was assigned to each participant and confidentiality was guaranteed on all information obtained. The trial was conducted in accord with the Declaration of Helsinki and Good Clinical Practice.

Funding

This study has been funded with a grant FIB-PI14-04 from the Foundation for Biomedical Research of the Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author information

Affiliations

  1. Hospital Universitario Príncipe de Asturias, Ctra de Meco s/n, 28805, Alcalá de Henares, Madrid, Spain

    Gerardo Rojo-Marcos & Juan Cuadros-González

  2. Instituto de Salud Carlos III, Majadahonda, Madrid, Spain

    José Miguel Rubio-Muñoz

  3. Ospedale Sacro Cuore - Don Calabria, Negrar, Verona, Italy

    Andrea Angheben & Federico Gobbi

  4. Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France

    Stephane Jaureguiberry

  5. Hospital Universitario La Paz-Carlos III, Madrid, Spain

    Silvia García-Bujalance

  6. Spedali Civili Hospital, University of Brescia, Brescia, Italy

    Lina Rachele Tomasoni

  7. Hospital Clinic, Barcelona, Spain

    Natalia Rodríguez-Valero

  8. Hospital Universitario de Fuenlabrada, Madrid, Spain

    José Manuel Ruiz-Giardín

  9. Hospital del Poniente-El Ejido, Almería, Spain

    Joaquín Salas-Coronas

  10. Hospital General Universitario de Valencia, Valencia, Spain

    Magdalena García-Rodríguez

  11. Hospital Vall D´Hebron-Drassanes, Barcelona, Spain

    Israel Molina-Romero

  12. Hospital Universitario Ramón y Cajal, Madrid, Spain

    Rogelio López-Vélez

  13. Hospital Universitario Gregorio Marañón, Madrid, Spain

    María Calderón-Moreno

  14. Hospital Universitario de Guadalajara, Guadalajara, Spain

    Esteban Martin-Echevarría

  15. Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain

    Matilde Elía-López

  16. Complejo Hospitalario Universitario de Santiago de Compostela, A Coruña, Spain

    José Llovo-Taboada

Authors
  1. Gerardo Rojo-Marcos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. José Miguel Rubio-Muñoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea Angheben
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephane Jaureguiberry
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Silvia García-Bujalance
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lina Rachele Tomasoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Natalia Rodríguez-Valero
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. José Manuel Ruiz-Giardín
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Joaquín Salas-Coronas
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Juan Cuadros-González
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Magdalena García-Rodríguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Israel Molina-Romero
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Rogelio López-Vélez
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Federico Gobbi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. María Calderón-Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Esteban Martin-Echevarría
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Matilde Elía-López
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. José Llovo-Taboada
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

TropNet Plasmodium ovale investigator group

Corresponding author

Correspondence to Gerardo Rojo-Marcos.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rojo-Marcos, G., Rubio-Muñoz, J.M., Angheben, A. et al. Prospective comparative multi-centre study on imported Plasmodium ovale wallikeri and Plasmodium ovale curtisi infections. Malar J 17, 399 (2018). https://doi.org/10.1186/s12936-018-2544-6

Download citation

Keywords

  • Plasmodium ovale curtisi
  • Plasmodium ovale wallikeri
  • Comparative study
  • Thrombocytopenia
  • INR
  • Antimalarials
  • Diabetes mellitus

Malaria Journal

ISSN: 1475-2875

Contact us